Paradoxically, inhibiting ITK in T cells may be efficacious in cancer, as this may enhance Th1-skewing of CD4+ T-cells and thereby improved memory formation and functionality of CD8+ T-cells, potentially leading to improved anti-tumor immunity [243, 247]. The gene discussed is CD4; the disease is cancer.